Pharmacology

vancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safetyvancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safety

vancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safetyvancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safety

vancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safetyvancomycin, MRSA, methicillin-resistant Staphylococcus aureus, neprotoxicity, hemodynamics, efficacy, safety

fenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetesfenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetes

fenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetesfenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetes

fenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetesfenofibrate, renal function, microalbuminuria, cystatin C, creatinine clearance, estimated glomular filtration rate, albumin excretion rate, albumin-to-creatinine ratio, protein excretion, type 2 diabetes

pneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumoniapneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumonia

pneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumoniapneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumonia

pneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumoniapneumonia, acid-suppressing drugs, proton pump inhibitors, PPIs, histamine 2-receptor antagonists, H2s, gastric pH, community-acquired pneumonia

treatment, pulmonary, pulmonary arterial hypertension, PAH, epoprostenol, EPO, prostacyclin analogues, PCA, endothelin receptor antagonists, phosphodiesterase-type-5 inhibitors, pulmonary arterial pressure, PAPtreatment, pulmonary, pulmonary arterial hypertension, PAH, epoprostenol, EPO, prostacyclin analogues, PCA, endothelin receptor antagonists, phosphodiesterase-type-5 inhibitors, pulmonary arterial pressure, PAP

treatment, pulmonary, pulmonary arterial hypertension, PAH, epoprostenol, EPO, prostacyclin analogues, PCA, endothelin receptor antagonists, phosphodiesterase-type-5 inhibitors, pulmonary arterial pressure, PAPtreatment, pulmonary, pulmonary arterial hypertension, PAH, epoprostenol, EPO, prostacyclin analogues, PCA, endothelin receptor antagonists, phosphodiesterase-type-5 inhibitors, pulmonary arterial pressure, PAP

treatment, pulmonary, pulmonary arterial hypertension, PAH, epoprostenol, EPO, prostacyclin analogues, PCA, endothelin receptor antagonists, phosphodiesterase-type-5 inhibitors, pulmonary arterial pressure, PAPtreatment, pulmonary, pulmonary arterial hypertension, PAH, epoprostenol, EPO, prostacyclin analogues, PCA, endothelin receptor antagonists, phosphodiesterase-type-5 inhibitors, pulmonary arterial pressure, PAP

nonsteroidal anti-inflammatory drugs, NSAIDs, pericardial effusions, diclofenac, pericardiocentesisnonsteroidal anti-inflammatory drugs, NSAIDs, pericardial effusions, diclofenac, pericardiocentesis

nonsteroidal anti-inflammatory drugs, NSAIDs, pericardial effusions, diclofenac, pericardiocentesisnonsteroidal anti-inflammatory drugs, NSAIDs, pericardial effusions, diclofenac, pericardiocentesis

nonsteroidal anti-inflammatory drugs, NSAIDs, pericardial effusions, diclofenac, pericardiocentesisnonsteroidal anti-inflammatory drugs, NSAIDs, pericardial effusions, diclofenac, pericardiocentesis

morphine, combat, injury, trauma, posttraumatic stress disorder, PTSD, Iraq, opiates, anxiolytics, beta-adrenergic antagosistmorphine, combat, injury, trauma, posttraumatic stress disorder, PTSD, Iraq, opiates, anxiolytics, beta-adrenergic antagosist

morphine, combat, injury, trauma, posttraumatic stress disorder, PTSD, Iraq, opiates, anxiolytics, beta-adrenergic antagosistmorphine, combat, injury, trauma, posttraumatic stress disorder, PTSD, Iraq, opiates, anxiolytics, beta-adrenergic antagosist

morphine, combat, injury, trauma, posttraumatic stress disorder, PTSD, Iraq, opiates, anxiolytics, beta-adrenergic antagosistmorphine, combat, injury, trauma, posttraumatic stress disorder, PTSD, Iraq, opiates, anxiolytics, beta-adrenergic antagosist

levonorgestrel, DoD, basic core formulary, Plan B, Plan B One Step, abortion, emergency contraception, contraception, birth control, nonprescriptionlevonorgestrel, DoD, basic core formulary, Plan B, Plan B One Step, abortion, emergency contraception, contraception, birth control, nonprescription

levonorgestrel, DoD, basic core formulary, Plan B, Plan B One Step, abortion, emergency contraception, contraception, birth control, nonprescriptionlevonorgestrel, DoD, basic core formulary, Plan B, Plan B One Step, abortion, emergency contraception, contraception, birth control, nonprescription

levonorgestrel, DoD, basic core formulary, Plan B, Plan B One Step, abortion, emergency contraception, contraception, birth control, nonprescriptionlevonorgestrel, DoD, basic core formulary, Plan B, Plan B One Step, abortion, emergency contraception, contraception, birth control, nonprescription

aspirin, peptic ulcer, cardiovascular disease, cerebrovascular disease, bleeding, antisecretory therapy, antiplatelet, endoscopic, digestive disease, hemostasis, pantoprazoleaspirin, peptic ulcer, cardiovascular disease, cerebrovascular disease, bleeding, antisecretory therapy, antiplatelet, endoscopic, digestive disease, hemostasis, pantoprazole

aspirin, peptic ulcer, cardiovascular disease, cerebrovascular disease, bleeding, antisecretory therapy, antiplatelet, endoscopic, digestive disease, hemostasis, pantoprazoleaspirin, peptic ulcer, cardiovascular disease, cerebrovascular disease, bleeding, antisecretory therapy, antiplatelet, endoscopic, digestive disease, hemostasis, pantoprazole

aspirin, peptic ulcer, cardiovascular disease, cerebrovascular disease, bleeding, antisecretory therapy, antiplatelet, endoscopic, digestive disease, hemostasis, pantoprazoleaspirin, peptic ulcer, cardiovascular disease, cerebrovascular disease, bleeding, antisecretory therapy, antiplatelet, endoscopic, digestive disease, hemostasis, pantoprazole

diabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreasdiabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreas

diabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreasdiabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreas

diabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreasdiabetes, liraglutide, glycemic, type 2 diabetes, exenatide, insulin, glucagon-like peptide-1, GLP-1, glycemic control, endogenous, once-daily, clinical trial, adjunct therapy, FDA, drug, treatment, pancreas

beta-blockers, timing, dosage, Perioperative Ischemic Evaluation trial, POISE, stroke, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography trials, DECREASE, metoprolol, bisoprolol, antenolol,beta-blockers, timing, dosage, Perioperative Ischemic Evaluation trial, POISE, stroke, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography trials, DECREASE, metoprolol, bisoprolol, antenolol,

beta-blockers, timing, dosage, Perioperative Ischemic Evaluation trial, POISE, stroke, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography trials, DECREASE, metoprolol, bisoprolol, antenolol,beta-blockers, timing, dosage, Perioperative Ischemic Evaluation trial, POISE, stroke, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography trials, DECREASE, metoprolol, bisoprolol, antenolol,

beta-blockers, timing, dosage, Perioperative Ischemic Evaluation trial, POISE, stroke, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography trials, DECREASE, metoprolol, bisoprolol, antenolol,beta-blockers, timing, dosage, Perioperative Ischemic Evaluation trial, POISE, stroke, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography trials, DECREASE, metoprolol, bisoprolol, antenolol,